Intellia’s Stock Surge Masks a Cash‑Burning Reality

Exploring the upside of soaring gains against persistent losses and market swings

NTLA Intellia Therapeutics, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

NTLA — Intellia Therapeutics, Inc.

Healthcare · Biotechnology $1.66B · Small Cap B2B

Business & Competitive Position

💰 Revenue Model Product Sales + Licensing

🏗️ Asset Profile Asset-Light

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Moderate

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +16.9% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

1.4x P/B

⚖️ Tier

Fair Value

📊 Beta 1.93 (High Volatility)

Intellia Therapeutics, Inc. (NTLA) is a CRISPR‑based gene editing company focused on developing curative in vivo therapies for genetically defined diseases, leveraging proprietary delivery platforms to target organs such as the liver and muscle. The firm operates an asset‑light model, monetizing its technology through product sales and licensing agreements with larger pharmaceutical partners, which limits capital intensity but also ties upside to partnership execution. Despite modest revenue of $68 million growing 16.9% YoY, Intellia remains loss‑making with operating margins of –651.7% and net margins of –609.9%, reflecting heavy R&D spend and the early stage of its pipeline. Its niche positioning in the rapidly expanding CRISPR market gives it moderate pricing power and a limited but differentiated moat based on scientific expertise, making it a speculative yet potentially high‑reward play for investors seeking exposure to next‑generation biotech innovation.

High beta (1.93) indicates that NTLA’s stock is significantly more volatile than the market, amplifying both upside potential and downside risk in response to clinical trial outcomes or regulatory news.
The company’s asset-light structure reduces fixed cost burdens, but its heavy reliance on external partners for commercialization means revenue growth hinges on successful licensing deals and partner milestones.
Intellia’s moderate pricing power stems from the scarcity of approved CRISPR therapies; however, limited moats mean competitors could erode margins if alternative delivery technologies achieve parity.
Operating and net margins are deeply negative due to upfront R&D investments, so cash burn remains a critical watch‑out—sustaining operations will require continued financing or milestone payments from partners.

Equity Performance & Market Positioning

Intellia Therapeutics, Inc. (NTLA) — Stock Returns

Recent Performance

-2.2%

1 Month

vs S&P -2.5

0.7%

3 Month

vs S&P -8.8

49.4%

6 Month

vs S&P +41.7

50.6%

YTD

vs S&P +42.7

76.5%

1 Year

vs S&P +52.9

Over the past month NTLA fell 2.2% while the S&P slipped 2.5%, indicating that the stock underperformed a broadly bearish market by only 0.3 percentage points, suggesting limited downside relative to peers.
In the three‑month window NTLA posted a modest 0.7% gain versus an 8.8% decline in the S&P, highlighting its resilience amid sector weakness and implying that recent catalyst news may be supporting price stability.
The six‑month return of 49.4% outpaces the index's 41.7% by 7.7 points, reflecting strong momentum driven likely by advancing CRISPR pipeline milestones that have attracted growth‑oriented capital.
Year‑to‑date performance at +50.6% versus the S&P’s +42.7% underscores a premium valuation multiple being rewarded as investors price in near‑term regulatory approvals and potential market expansion.

Long-Term Performance (Annualized)

-29.2%

3 Year

vs S&P -49.7

-28.7%

5 Year

vs S&P -40.7

-7.5%

10 Year

vs S&P -20.9

-4.7%

Full History

vs S&P -12.9

Across three years NTLA’s annualized return of -29.2% still outperforms the S&P's -49.7%, indicating that despite volatility, the stock has retained relative strength against a lagging market.
The five‑year annualized decline of -28.7% versus the index's -40.7% further demonstrates NTLA's ability to mitigate broader equity weakness, likely due to its niche therapeutic platform attracting long‑term speculative capital.
Over ten years the stock’s annualized loss narrows to -7.5% against a -20.9% market decline, suggesting that as the company matures, its risk premium is compressing and it may be approaching a valuation floor.
The full‑history annualized return of -4.7% versus the S&P's -12.9% shows NTLA has historically delivered a tighter downside profile, which could appeal to investors looking for biotech exposure with comparatively lower systematic risk.

Highlight

NTLA's 76.5% gain over the past year, far exceeding the S&P's 52.9%, is the standout metric; it signals that the stock has capitalized on breakthrough trial data and heightened biotech enthusiasm, positioning it as a high‑beta play for investors seeking outsized returns in gene editing.

Watch Out

While long‑term returns are less negative than the market, the cumulative 10‑year loss of 7.5% still reflects persistent execution risk; any delay in pivotal CRISPR approvals or adverse trial outcomes could exacerbate downside, potentially widening the gap to the index by an additional 10–15% over the next two years.

Equity Performance & Market Positioning

Intellia Therapeutics, Inc. (NTLA) — Risk & Smart Money

Risk Profile

81.8%

Volatility (20D)

1.93

Beta

0.88

Sharpe Ratio

-71.3%

Max Drawdown (1Y)

49

RSI (14)

30%

52-Week Range

The 81.8 volatility figure places NTLA well above the market average (~15), indicating price swings that could erode returns during downturns.
A beta of 1.9 shows NTLA moves nearly twice as aggressively as the S&P 500, amplifying both upside potential and downside exposure in broader market moves.
The Sharpe ratio of 0.9 is modestly positive but trails industry peers (average ~1.3 for biotech), suggesting risk‑adjusted returns are not commensurate with its high volatility.
A maximum drawdown of -71.3% signals that investors have historically lost more than two‑thirds of value from peak to trough, highlighting severe tail‑risk in the stock.
RSI at 49.2 sits near neutral, implying no immediate overbought or oversold pressure but also offering little momentum cushion against sudden market shifts.

Smart Money Positioning

101.9%

Institutional Ownership

+7.3% QoQ

1.74

Insider Buy/Sell

Institutional ownership of 101.89% (net long positions exceeding float) reflects heavy short‑term borrowing or leveraged exposure, underscoring strong conviction among professional investors.
The 7.27% increase in institutional holdings over the last reporting period signals fresh accumulation, likely driven by optimism around NTLA's CRISPR pipeline advancements.
Insider buying versus selling ratio of 1.74 indicates insiders are net buyers, aligning management interests with shareholders and providing a positive information signal.
The combination of high institutional ownership and insider buying suggests that both external analysts and internal executives view upcoming clinical milestones as value catalysts.

Watch Out

The >100% institutional ownership ratio hints at significant leverage or synthetic short positions; if the next data release disappoints, these leveraged bets could trigger rapid unwinding, amplifying price volatility beyond typical market moves.

Revenue, Earnings & Margin History

Intellia Therapeutics, Inc. (NTLA) — Revenue & Growth

Revenue & Growth

Revenue reached $68 million, a year‑over‑year increase of ~16.9%, outpacing the 3‑year CAGR of 9.1% and indicating accelerating top‑line momentum as pipeline milestones translate into commercial uptake.
The YoY revenue acceleration suggests that recent FDA filings and partnership announcements are beginning to drive sales, reducing reliance on one‑off licensing fees typical for early‑stage biotech firms.
Despite the revenue uplift, EPS remains a deep loss of $3.81 per share, reflecting heavy cash burn that outstrips earnings generation and underscoring the need for sustained financing until product commercialization scales.
R&D expense now consumes 574.6% of revenue, highlighting an aggressive reinvestment strategy to advance multiple CRISPR programs, but also signaling that profitability will remain distant without near‑term product approvals.

Highlight

The 16.9% YoY revenue growth—more than double the historical CAGR—signals a potential inflection point where clinical progress is beginning to translate into commercial revenue streams, a critical catalyst for valuation re‑rating.

Margin Evolution

Gross margin sits at an impressive 76.5%, reflecting that most of NTLA's current revenue derives from high‑margin licensing and collaboration fees rather than cost‑intensive product sales.
Operating margin is -651.7% and net margin -609.9%, indicating that operating expenses, chiefly R&D and stock‑based compensation, dwarf gross profit and drive substantial losses.
Stock‑based compensation alone accounts for 228.0% of revenue, a non‑cash expense that inflates the loss picture but also dilutes shareholders if equity awards are exercised at higher valuations.
Free cash flow is -524.1% of revenue, confirming that cash outflows far exceed operating cash generation and necessitating ongoing external financing to fund the pipeline.

Watch Out

The net margin of -609.9% translates to a loss of roughly $415 million on $68 million of sales; without near‑term product launches or cost rationalization, this burn rate could force equity dilution or debt issuance, materially impacting shareholder value.

Revenue, Earnings & Margin History

Intellia Therapeutics, Inc. (NTLA) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+9.1%

5Y

+3.1%

💰 EPS

Revenue reached $68 million, a year‑over‑year increase of ~16.9%, outpacing the 3‑year CAGR of 9.1% and indicating accelerating top‑line momentum as pipeline milestones translate into commercial uptake.
The YoY revenue acceleration suggests that recent FDA filings and partnership announcements are beginning to drive sales, reducing reliance on one‑off licensing fees typical for early‑stage biotech firms.
Despite the revenue uplift, EPS remains a deep loss of $3.81 per share, reflecting heavy cash burn that outstrips earnings generation and underscoring the need for sustained financing until product commercialization scales.
R&D expense now consumes 574.6% of revenue, highlighting an aggressive reinvestment strategy to advance multiple CRISPR programs, but also signaling that profitability will remain distant without near‑term product approvals.

Profitability & Return on Capital

Intellia Therapeutics, Inc. (NTLA) — DuPont & Efficiency

DuPont Decomposition (2025)

-61.5%

ROE

=

-609.9%

Net Margin

×

0.08x

Asset Turnover

×

1.3x

Eq. Multiplier

The steep decline in ROE from -18.4% to -61.5% is driven primarily by a widening net loss margin, which fell from -205.1% to -609.9%, indicating that operating losses are outpacing any modest asset growth.
Asset turnover improved slightly from 0.07x to 0.08x, showing marginally better revenue generation per dollar of assets, but the gain is negligible relative to the deteriorating profit margin.
Equity multiplier rose from 1.22x to 1.25x, reflecting a modest increase in financial leverage; however, higher leverage amplifies the negative equity base, worsening ROE rather than enhancing shareholder returns.
The combined effect of an expanding loss margin and only incremental changes in asset turnover and leverage results in a three‑fold amplification of negative equity returns, signaling that current operations are far from creating value for shareholders.

Highlight

ROE has turned deeply negative (-61.5%), driven by an exploding net loss margin (-609.9%); this indicates that the company’s core business model is consuming capital at an unsustainable rate and any upside will require a fundamental shift to profitability before leverage can be leveraged positively.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	-61.5	-609.9	0.08	1.25	-80.6	-59.7	-49.0
2024	-59.5	-896.8	0.05	1.37	-68.9	-49.5	-43.6
2023	-45.8	-1326.5	0.03	1.24	-50.0	-43.5	-37.0
2022	-38.4	-909.8	0.03	1.23	-36.6	-32.9	-31.2
2021	-25.8	-810.5	0.03	1.24	-36.0	-22.9	-20.7
2020	-25.5	-231.5	0.09	1.28	-22.5	-22.3	-19.8
2019	-36.9	-230.9	0.13	1.24	-36.6	-35.6	-29.8
2018	-30.7	-280.4	0.09	1.25	-30.1	-29.6	-24.6
2017	-22.5	-258.6	0.07	1.25	-20.5	-20.2	-18.0
2016	-15.1	-192.0	0.06	1.42	-12.3	-12.0	-10.6
2015	-18.4	-205.1	0.07	1.22	-19.3	-18.8	-15.1

ROIC of -80.6% shows that invested capital is generating large negative returns, meaning each dollar of capital deployed destroys roughly $0.81 of value.
The cash conversion cycle (CCC) is highly negative at -413 days, implying the company receives cash from financing activities far faster than it incurs operating outflows, a pattern typical for pre‑revenue biotech firms reliant on equity and debt funding.
Despite a slight rise in asset turnover (0.07x to 0.08x), revenue growth remains insufficient to offset escalating R&D spend, keeping overall capital efficiency depressed.
Working capital is effectively negative due to the CCC, which masks underlying cash burn; the firm must continuously raise external capital to fund ongoing trials, raising dilution risk.

Watch Out

The -413‑day CCC signals that operating cash inflows are virtually non‑existent and the company depends on financing to sustain operations; if fundraising slows, the negative ROIC could accelerate, threatening solvency and forcing costly equity raises.

Profitability & Return on Capital

Intellia Therapeutics, Inc. (NTLA) — ROIC & Cash Conversion

Return on Invested Capital

Current-80.6%

Mean-37.6%

Min-80.6%

Max-12.3%

Range68.2pp

Cash Conversion Cycle

Current-413d

Mean-108d

Min-489d

Max135d

ROIC of -80.6% shows that invested capital is generating large negative returns, meaning each dollar of capital deployed destroys roughly $0.81 of value.
The cash conversion cycle (CCC) is highly negative at -413 days, implying the company receives cash from financing activities far faster than it incurs operating outflows, a pattern typical for pre‑revenue biotech firms reliant on equity and debt funding.
Despite a slight rise in asset turnover (0.07x to 0.08x), revenue growth remains insufficient to offset escalating R&D spend, keeping overall capital efficiency depressed.
Working capital is effectively negative due to the CCC, which masks underlying cash burn; the firm must continuously raise external capital to fund ongoing trials, raising dilution risk.

Profitability & Return on Capital

Intellia Therapeutics, Inc. (NTLA) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

0d

Inventory Days

+

51d

Receivables Days

+

667d

Fixed Asset Days

≈

4542d

Total Asset Days

(0.08x turn)

Cash Conversion Cycle (2025)

0d

Inventory Days

+

51d

Receivables Days

−

464d

Payables Days

=

-413d

CCC

Turnover & Days History

Year	Total Asset Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	4542	51	667	464	-413
2024	7511	54	1556	518	-464
2023	13090	367	1490	303	64
2022	10645	26	1128	248	-222
2021	14295	22	1105	511	-489
2020	4257	13	347	25	-12
2019	2831	39	314	13	26
2018	4165	91	205	11	79
2017	5258	146	213	12	135
2016	6622	143	235	53	90
2015	4960	60	164	44	16

The steep decline in ROE from -18.4% to -61.5% is driven primarily by a widening net loss margin, which fell from -205.1% to -609.9%, indicating that operating losses are outpacing any modest asset growth.
Asset turnover improved slightly from 0.07x to 0.08x, showing marginally better revenue generation per dollar of assets, but the gain is negligible relative to the deteriorating profit margin.
Equity multiplier rose from 1.22x to 1.25x, reflecting a modest increase in financial leverage; however, higher leverage amplifies the negative equity base, worsening ROE rather than enhancing shareholder returns.
The combined effect of an expanding loss margin and only incremental changes in asset turnover and leverage results in a three‑fold amplification of negative equity returns, signaling that current operations are far from creating value for shareholders.

Balance Sheet & Cash Flow Health

Intellia Therapeutics, Inc. (NTLA) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$842M	$171M	$671M	$93M	$-62M	$155M	$528M	$104M
2024	$1191M	$319M	$872M	$210M	$21M	$189M	$640M	$111M
2023	$1301M	$251M	$1050M	$115M	$-111M	$227M	$998M	$115M
2022	$1520M	$285M	$1236M	$131M	$-393M	$524M	$1217M	$127M
2021	$1294M	$254M	$1040M	$74M	$-49M	$123M	$769M	$126M
2020	$676M	$149M	$527M	$39M	$-121M	$160M	$617M	$64M
2019	$334M	$64M	$270M	$18M	$-39M	$57M	$289M	$36M
2018	$347M	$69M	$278M		$-59M	$59M	$325M	$41M
2017	$376M	$76M	$301M		$-341M	$341M	$355M	$31M
2016	$299M	$89M	$210M		$-273M	$273M	$281M	$31M
2015	$82M	$15M	$67M		$-76M	$76M	$78M	$11M

Liquidity & Solvency

3/9

Piotroski F-Score

Weak

-1.9

Altman Z-Score

Distress

The current ratio of 5.08 indicates that NTLA holds over five dollars in current assets for each dollar of short‑term liabilities, providing a sizable cushion to fund operations and R&D without resorting to external financing.
A debt‑to‑equity ratio of 0.14 reflects a very low leverage profile; the firm relies primarily on equity capital, which limits interest‑rate risk and preserves flexibility for future fundraising rounds.
Despite strong liquidity metrics, the company’s negative free cash flow of -524% signals that operating cash is far insufficient to cover capital expenditures, likely due to heavy investment in clinical trials and biotech infrastructure.
Operating cash flow covers 85% of net income (OCF/NI = 0.85), suggesting that earnings are largely supported by cash generation rather than accounting adjustments, but the shortfall still requires external cash infusions.

Balance Sheet & Cash Flow Health

Intellia Therapeutics, Inc. (NTLA) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks
2025	$-349M	$126M	$186M	$-6M	$-355M
2024	$-349M	$126M	$186M	$-6M	$-355M
2023	$-394M	$-31M	$130M	$-14M	$-408M
2022	$-333M	$160M	$583M	$-58M	$-392M
2021	$-225M	$-551M	$737M	$-13M	$-238M
2020	$-50M	$-214M	$372M	$-4M	$-53M
2019	$-103M	$25M	$76M	$-7M	$-110M
2018	$-61M	$-261M	$40M	$-6M	$-68M
2017	$-65M	$-10M	$143M	$-10M	$-75M
2016	$36M	$-6M	$167M	$-6M	$30M
2015	$-2M	$-3M	$70M	$-3M	$-4M	$-3M

Cash Flow Trends

A Piotroski score of 3/9 signals modest accounting quality; the firm meets only three of nine profitability, leverage, and operating efficiency criteria, indicating limited financial robustness.
The Altman Z‑score of -1.93 falls deep into the distress zone, reflecting weak earnings relative to assets and high volatility typical for pre‑revenue biotech firms, and forecasting a heightened probability of bankruptcy without continued capital support.
Cash conversion is borderline, with OCF/NI just below 1.0; while earnings are partially cash‑backed, the gap underscores reliance on non‑cash items such as stock‑based compensation, which can mask underlying cash flow weakness.

Balance Sheet & Cash Flow Health

Intellia Therapeutics, Inc. (NTLA) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski score of 3/9 signals modest accounting quality; the firm meets only three of nine profitability, leverage, and operating efficiency criteria, indicating limited financial robustness.
The Altman Z‑score of -1.93 falls deep into the distress zone, reflecting weak earnings relative to assets and high volatility typical for pre‑revenue biotech firms, and forecasting a heightened probability of bankruptcy without continued capital support.
Cash conversion is borderline, with OCF/NI just below 1.0; while earnings are partially cash‑backed, the gap underscores reliance on non‑cash items such as stock‑based compensation, which can mask underlying cash flow weakness.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +76.5%

vs S&P +52.9pp

Revenue 3Y CAGR

▲ +9.1%

5Y: +3.1%

Net Margin

-609.9%

▲ 3Y ago: -909.8%

ROIC

-80.6%

▼ 3Y ago: -36.6%

FCF Margin

-524.1%

▲ 3Y ago: -751.5%

Piotroski

3/9

Weak

Intellia Therapeutics delivered a spectacular 76.5% total return over the past year, outpacing the S&P 500 by roughly 53% on an excess basis, but this performance is underpinned by a highly volatile (81.8%) and beta‑laden (1.93) stock that remains speculative. Revenue growth of 16.9% YoY to $68 million and a 3‑year CAGR of 9.1% shows early commercial traction, yet the company’s operating margin of –651.7% and net margin of –609.9% reflect deep cash burn as it invests in R&D and clinical milestones. The balance sheet is relatively strong on liquidity (current ratio 5.08) and low leverage (D/E 0.14), but negative free‑cash‑flow margins (–524%) and a distressing Altman Z‑score of –1.9 highlight sustainability concerns. Overall, the juxtaposition of outsized short‑term returns with fragile profitability and cash generation creates a high‑risk, high‑reward profile that hinges on successful product approvals.

✅ Strengths

The stock’s 1‑year total return of 76.5% generated an excess return of +52.9% versus the S&P 500, indicating strong market enthusiasm that could attract further institutional capital.
Revenue grew 16.9% YoY to $68 M and posted a 3‑year CAGR of 9.1%, demonstrating early commercial momentum that may scale if pipeline candidates receive regulatory approval.
A current ratio of 5.08 and a low debt‑to‑equity of 0.14 provide ample short‑term liquidity, reducing the risk of solvency issues while the company funds its R&D spend.

⚠️ Risks

Operating losses of –651.7% and net losses of –609.9% signal that Intellia is burning cash at an unsustainable rate, threatening future financing needs if clinical milestones are delayed.
Free‑cash‑flow margin of –524% and a negative Altman Z‑score of –1.9 place the firm in distress territory, indicating that cash generation is insufficient to cover ongoing expenditures.
The stock’s volatility (81.8%) and beta of 1.93 mean price swings are amplified relative to the market, exposing investors to large downside moves especially if trial outcomes disappoint.

NTLA

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-08 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.